NuCana reports third quarter net loss of £0.3 million

NuCana plc reported a net loss of £0.3 million for the third quarter ended September 30, 2025, including other income of £2.7 million, compared to a net loss of £4.5 million for the same period in 2024. Basic and diluted loss per ordinary share was £0.00 for the third quarter of 2025, compared to £0.07 in the third quarter of 2024. For the nine months ended September 30, 2025, the company reported a net loss of £26.9 million, up from a net loss of £18.3 million for the same period in 2024. As of September 30, 2025, cash and cash equivalents totaled £25.2 million, up from £6.7 million at December 31, 2024. In July 2025, NuCana raised £19.0 million in gross proceeds through its at-the-market program and eliminated all remaining Series A Warrants from the May 2025 financing. The company expects its cash position to fund operations into 2029. Business developments included the announcement of encouraging data for lead anti-cancer medicines NUC-7738 and NUC-3373, with initial data from an expansion study of NUC-7738 anticipated in the fourth quarter of 2025 and final data expected in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NuCana plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574393-en) on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)